Guide to 177Lu-Prostate Specific Membrane Antigen Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer in Slovakia

Abstract Radioligand therapy with 177 Lu-Prostate Specific Membrane Antigen is a very promising treatment option for patients with prostate cancer. In the past ten years it started to be used as one of the final options in patients with metastatic, castration resistant prostate cancer, after previously exploiting all the common treatments. In Slovakia, this treatment has been available since the beginning of the year 2020. In this time, we have been able to adopt many of the recommendations from the European guidelines and adapt the rest to the clinical and national legislative requirements. In the time period between February 2020 and June 2024, we treated 104 patients and administered total of 362 cycles of the radioligand therapy with 177 Lu-Prostate Specific Membrane Antigen. Although the numbers of our patients suitable for systemic evaluation are for now rather small, our result has so far showed the correlation with some of the largest multicentric trials. More patients will be included in the further evaluation with upcoming months, and more precise data will be available.